# INDEX

Volume Six — January through December 1990

## *the journal of Pharmacy Technology*


| | | | |
|---|---|---|---|
| January/February | Pages 1-48 | July/August | Pages 137-184 |
| March/April | Pages 49-88 | September/October | Pages 185-224 |
| May/June | Pages 89-136 | November/December | Pages 225-262 |


### A-B


**Acetaminophen,** interference with amino acid analysis (A) 66
**Acetylcysteine,** interference with amino acid analysis (A) 66
**Acid phosphatase,** laboratory test (A) 22
**Ackerman, Bruce H.** (author) The New Fluoroquinolones: Correlating In Vitro Findings and Clinical Experience (A) 5
**Actifed,** interference with amino acid analysis (A) 66
**Adenosine,** approved (WN) 181
**Admixtures,** training manual (NP) 4
**Advances in Hospital Pharmacy Computing** (A) 197
**Adverse drug reactions,** antiepileptic drugs, 147; benzodiazepines (A) 234; computer reporting (A) 198; flumazenil (A) 100; nicardipine hydrochloride (A) 97; pentamidine (A) 58
**Aerosolization,** reduction of by CytoGuard (WN) 45
**AIDS,** *Pneumocystis carinii* pneumonia prophylaxis (A) 57; vaccine, clinical trials approved (PF) 132, prevents HIV infection (PF) 132
**Alanine aminotransferase,** laboratory test (A) 22
**Albumin,** laboratory test (A) 22
**Aldolase,** laboratory test (A) 22
**Alkaline phosphatase,** laboratory test (A) 22


#### INDEX ABBREVIATIONS

| | |
|---|---|
| A: | Article |
| AN: | Association News |
| E: | Editorial |
| HQ: | Historical Quote |
| ibc: | Inside back cover |
| ifc: | Inside front cover |
| L: | Letter |
| NP: | New Publications |
| PF: | Pharmacy Focus |
| TT: | Therapeutic Trends |
| U: | Updating Your Skills |
| WN: | What's New |


**Alzheimer's disease,** new enzyme discovered (WN) 85
**American Society of Hospital Pharmacists,** advisory on handling hazardous drugs (PF) 176; development of technician services (A) 169; grants available (PF) 219; Task Force on Technical Personnel, recommendations (A) 170
**Amino acid analysis,** drug interferences with (A) 64
**Aminocaproic acid,** interference with amino acid analysis (A) 66
**Ammonia,** interference with amino acid analysis (A) 66; laboratory test (A) 23
**Amoxicillin,** interference with amino acid analysis (A) 66
**Amphetamine sulfate,** interference with amino acid analysis (A) 66
**Ampicillin,** interference with amino acid analysis (A) 66
**Amylase,** laboratory test (A) 23
**Analysis and Quality Control of Polyherbal Drugs: A Focus on the Herbal Cream Herbinol** (A) 166
**Anderson, Roger W.** (author) Technicians and the Goal of Excellence (A) 169
**Anesthesia,** drug trays, exchangeable (A) 192; flumazenil used to reverse benzodiazepine effects (A) 99
**Anistreplase,** approved, 181
**Announcements,** APT Greater Atlanta Chapter Southeast Regional Seminar, 235; Calling All Pharmacy Technicians! 252; International Conference for Pharmacy Technician Educators, 218; Pharmacy Technicians in the 90's 9th Annual Conference, 196; Tri-State Pharmacy Technician Symposium, 183
**Antibiotics,** fluoroquinolones (A) 5
**Antiepileptic drugs,** review (A) 146
**Aparicio, M.** (coauthor) see **Vazquez, A.,** 236
**Appropriateness of Switches from Prescription to Over-the-Counter Drug Status: Influence of Demographic and Practice Characteristics on Pharmacist Decision Making** (A) 239
**Arginine,** interference with amino acid analysis (A) 68
**Ascorbic acid,** interference with amino acid analysis (A) 68
**ASHP Advisory on Handling Hazardous Drugs** (PF) 176
**Aspartate aminotransferase,** laboratory test (A) 23
**Association News,** CNCAPT New Officers Elected, 39, 250; Convention '90 Successful, 249; Information About CAPT, 174; New Hampshire Society of Pharmacy Technicians, 174; New Officers for 1990-91 Announced, 174
**Association of Pharmacy Technicians,** continuing education test, 48, 88, 136, 184, 224, 256; convention 1990, MJ-ifc; new officers announced (AN) 174
**Athani, Anuradha V.** (author) Issues in Contemporary Drug Delivery, Part III. Pharmacokinetic/Pharmacodynamic Modeling (A) 200
**Author guidelines,** JF-ifc, MA-ifc, JA-ifc, SO-ifc, ND-ifc
**Autio, L.** (author) Comment: Job Satisfaction Survey (L) 228
**Azauridine triacetate,** interference with amino acid analysis (A) 68
**Bacteria Developing Resistance to Latest Antibiotics** (PF) 251
**Ballington, Don A.** (author) Pharmacy Technician Educator's Conference 1990: Summary Report (E) 185
**Banakar, Umesh V.** (author) Issues in Contemporary Drug Delivery, Part I: Fundamental Considerations (A) 75, Part II: Biopharmaceutical Considerations (A) 122; (coauthor) see **Athani, Anuradha V.,** 200
**Basic Concepts in Epilepsy** (A) 146
**Benzodiazepines,** effects reversed by flumazenil (A) 99; insomnia management (A) 231
**Bilirubin,** laboratory test (A) 24
**Birdwell, Stephen W.** (author) Community Pharmacists' Attitudes Toward the Expanding Role of Pharmacy Technicians (A) 212
**Blood pressure,** systemic, nicardipine's effects on (A) 94
**Bodurka, Ronald P.** (author) Comment: Demand Increases for Accredited Pharmacy Technicians (L) 228
**Bond, William S.** (author) Insomnia Manage-

ment and Hypnotic Benzodiazepine Therapeutics (A) 231
**Book Reviews,** see **Publications, New**
**Books Received,** 54, 143, 229
**Boyd, Eddie L.** (author) book review, 142
**Buelga, D. Santos** (coauthor) see **Vazquez, A.,** 236
**Butorphanol,** nasal spray more effective (PF) 82
**Byrd, William** (coauthor) see **Christie, Joan M.,** 192

## C-D

**Calcium,** laboratory test (A) 24
**Calcium-channel blockers,** nicardipine hydrochloride (A) 93
**California,** legal setback for technicians (A) 114
**Canadian Association of Pharmacy Technicians,** founding (AN) 174
**Cancer,** anorexia/cachexia, treatment with megestrol acetate (PF) 219; gastric, advances reported (PF) 40; sarcomas, MAID used in treatment of (PF) 41
**Capsaicin,** three-ounce size available (WN) 45
**Carbenicillin,** interference with amino acid analysis (A) 68
**Carbon dioxide,** laboratory test (A) 24
**Carboplatin,** approved (WN) 181
**Carpal tunnel syndrome,** see **Repetitive motion disorders**
**Carson, Deborah Stier** (coauthor) see **Gums, John G.,** 10
**Cascella, Peter J.** (coauthor) see **Powers, James E.,** 60
**Cefixime,** approved (WN) 181
**Cefmetazole,** approved (WN) 181
**Cefmetazole sodium,** marketing clearance obtained (WN) 45
**Central North Carolina Chapter Elects Officers** (AN) 250
**Cephalexin,** interference with amino acid analysis (A) 68
**Cephaloridine,** interference with amino acid analysis (A) 68
**Certification,** see **Credentialing**
**Chakravarthy, B.K.** (coauthor) see **Mangalan, S.,** 166
**Champaneri, Dipti K.** (coauthor) see **Mangalan, S.,** 166
**Child-Resistant Closures and Repetitive Motion Disorders** (W 253
**Chol[illegible]** laboratory te[illegible] (A) 25
**Cholesterol,** laboratory test (A) 25
**Cholesterol-HDL,** laboratory test (A) 25
**Christie, Joan M.** (author) Pharmacy Intervention and the Anesthesia Drug Exchange Drawer (A) 192
**Chronobiology,** interference with drug therapy (PF) 251
**Cimetidine,** use for unlabeled conditions (A) 17
**Circadian Rhythms** (PF) 251
**Cisplatin,** use for unlabeled conditions (A) 18
**Clomipramine,** approved (WN) 181
**Cloxacillin,** interference with amino acid analysis (A) 68
**Clozapine,** approved (WN) 181
**Cocchetto, David M.** (author) book review, 229
**Colistin,** interference with amino acid analysis (A) 68
**Comment: Technician Education** (L) 52
**Communication skills** (NP) 53
**Community Pharmacists' Attitudes Toward the Expanding Role of Pharmacy Technicians** (A) 212
**Comparison of Methods Used to Prepare Tablets for Nasogastric Tube Administration** (A) 60
**Compliance,** automated telephone message system introduced (WN) 223; Rx Alert introduced (WN) 134; Rx Register helpful for patients taking multiple medications (WN) 135
**Compounders,** new volumetric compounder introduced (WN) 44
**Computers,** use in hospital pharmacies (A) 197
**Convention '90 Successful** (AN) 249
**Creatine kinase,** laboratory test (A) 25
**Creatine kinase myocardial band,** laboratory test (A) 25
**Creatinine,** interference with amino acid analysis (A) 69; laboratory test (A) 25
**Credentialing,** technician certification (A) 171
**Cromolyn sodium,** in treatment of mastocytosis (WN) 86
**Cyclophosphamide,** use for unlabeled conditions (A) 18
**de Oca, Gelcys Montes** (coauthor) see **Gums, John G.,** 10
**Depakote sprinkle,** new formulation introduced (WN) 44
**Dermatology,** Upjohn and Owen/Galderma to copromote products (WN) 223
**Dexocine,** approved (WN) 181
**Dexter, Patricia D.** (author) book review, 4
**Diatrizoate meglumine,** interference with amino acid analysis (A) 69
**Dimetapp,** interference with amino acid analysis (A) 69
**Dispensing,** anesthesia drug exchange drawer (A) 192; needleless alternative (WN) 181; new vial improves compliance (WN) 86
**Dopamine hydrochloride,** interference with amino acid analysis (A) 69
**Dosage forms,** influence on drug efficacy (A) 122; (NP) 141
**Dosing,** computer allows exact dosing of insulin (WN) 223; use of models to predict patient response (A) 200
**Dosing techniques,** nasogastric tube (A) 60
**Doxorubicin hydrochloride,** use for unlabeled conditions (A) 18
**Drug Interferences with Amino Acid Analysis,** 63
**Drug approval,** FDA process (A) 15; new drugs (WN) 181
**Drug delivery,** conventional and unconventional systems (A) 80
**Drug development,** basic process (A) 75; physical-chemical considerations (A) 76; physiologic considerations (A) 79
**Drug information,** telephone message system introduced (WN) 223
**Drug status,** prescription vs. over-the-counter (A) 239
**Drugs,** cardiac (NP) 92; generic, quality assurance, 189; hazardous, ASHP issues advisory (PF) 176

## E-F

**Edetic acid,** interference with amino acid analysis (A) 69
**Editorials, Ballington, Don A.,** Pharmacy Technician Educator's Conference 1990: Summary Report, 185; **Whitney, Harvey A.K. Jr.,** Commitment: Holding Pharmacy Accountable for Technician Certification, 137; Job Satisfaction: *jPT* Survey Results, 1; Listening to Technicians, 49; Listening to Technicians—Revisited, 225; The U.S. Inspector General Views Technicians as Vital, 89
**Education, technician,** development of training programs (E) 185; educator recommendations (E) 188; (HQ) 211; pharmacist attitudes (A) 216
**Effect of Magnesium and Potassium on Cardiac Function: The Role of Spironolactone** (A) 10
**Elderly patients,** pharmacotherapy (U) 254; pharmacy success depends on their patronage (PF) 175; use of neuroleptics (PF) 219
**Enzyme,** Alzheimer's disease (WN) 85; macrooxyproteinase discovered (TT) 39
**Ephedrine,** interference with amino acid analysis (A) 69
**Epidermolysis bullosa,** treatment with phenytoin (A) 236
**Epilepsy,** seizure control (A) 146
**Epinephrine,** interference with amino acid analysis (A) 69
**Epoetin alfa,** approved (WN) 181
**Errors,** reduction by technicians (HQ) 9
**Erythromycin,** interference with amino acid analysis (A) 69
**Erythromycin gluceptate,** interference with amino acid analysis (A) 69
**Ethmozine Introduced** (WN) 253
**Ethylenediamine,** interference with amino acid analysis (A) 69
**Etoposide,** oral, increased efficacy over intravenous (PF) 41; use for unlabeled conditions (A) 18
**Fazio, Anthony** (coauthor) see **Yamreudeewong, Weeranuj,** 111
**Fernandez, G.** (coauthor) **see Vazquez A.,** 236
**Flumazenil,** reversal of benzodiazepine-induced sedation (A) 99
**Flumazenil: A Unique Medication to Reverse the Effects of Benzodiazepines** (A) 99
**Fluoroquinolones,** use in systemic infections (A) 5
**Fluorouracil,** effectiveness can be predicted (WN) 44; use for unlabeled conditions (A) 18
**Flurazepam,** use in insomnia treatment (A) 233
**Flutamide,** approved (WN) 181
**Food and Drug Administration,** drug approval process (A) 15; labeling requirements (A) 16
**Foust, Alice T.** (author) Comment: Technician Education (L) 52
**Fuerst, Robin H.** (author) Basic Concepts in Epilepsy (A) 146

## G-H

**Gamma-glutamyl transpeptidase,** laboratory test (A) 26
**Ganciclovir,** approved (WN) 181
**Garcia, M.J.** (coauthor) see **Vazquez A.,** 236
**Gentamicin sulfate,** interference with amino acid analysis (A) 69
**Gilbert's syndrome,** effect on drug metabolism (A) 111
**Givler, Donald N.** (coauthor) see **Yamreudeewong, Weeranuj,** 111
**Glaucoma,** drug absorption affected by time of day (PF) 132
**Glucose,** interference with amino acid analysis (A) 70; laboratory test (A) 26

**Goldberg, Michael E.** (author) Nicardipine Hydrochloride: The First Dihydropyridine Intravenous Calcium-Channel Antagonist (A) 93
**Gonzalez, A.C. Alonso** (coauthor) see **Vazquez A.**, 236
**Gores, Tommy M.** (author) New Technician Training Program (L) 140
**Goserelin,** approved (WN) 181
**Guidelines for the Practice of Pharmacy** (A) 29
**Gums, John G.** (author) Effect of Magnesium and Potassium on Cardiac Function: The Role of Spironolactone (A) 10; book review, 4
**Haley, Christopher J.** (coauthor) see **Massoummi, Fred,** 151; see **Picciano, Vincent,** 57
**Heart rate,** nicardipine's effects on (A) 94
**Hendrix, Grady H.** (coauthor) see **Gums, John G.,** 10
**Heparin,** interference with amino acid analysis (A) 70
**Herbinol,** quality control (A) 166
**Historical Quotes,** see **Quotes, Historical**
**HIV,** see **Human immunodeficiency virus**
**Hodgkin's disease,** replacement of MOPP as first-line therapy (PF) 40
**Human immunodeficiency virus,** prevented by AIDS vaccine (PF) 132
**Hurle, Dominguez-Gil, A.** (coauthor) see **Vazquez, A.,** 236
**Hyperalimentation,** interference with amino acid analysis (A) 70
**Hypokalemia,** effect of spironolactone (A) 13
**Hypomagnesemia,** effects on cardiac function (A) 10

## I-J

**Immunosuppressant,** Fujisawa to begin trials (WN) 85
**Indecainide,** approved (WN) 181
**Infectious disease,** therapy (NP) 190
**Information About CAPT** (AN) 174
**Insomnia,** treatment with benzodiazepines (A) 231
**Insomnia Management and Hypnotic Benzodiazepine Therapeutics** (A) 231
**Insulin,** computer makes exact dosing possible (WN) 223; Novo Nordisk subsidiary to market company products (WN) 46
**Interpretive Clinical Chemistry Laboratory Tests** (A) 21
**Interpreting Clinical Hematology Test Results** (A) 243
**Iotrolan,** approved (WN) 181
**Iron,** serum, laboratory test (A) 26; total iron-binding capacity, laboratory test (A) 26
**Isoniazid,** interference with amino acid analysis (A) 70
**Issues in Contemporary Drug Delivery, Part I: Fundamental Considerations** (A) 75; **Part II: Biopharmaceutical Considerations** (A) 122; **Part III: Pharmacokinetic/Pharmacodynamic Modeling** (A) 200
**Job satisfaction,** survey results (E) 1
**Johnston, Nita** (author) Comment: Technician Education (L) 52
**Jorgenson, James A.** (coauthor) see **Malatestinic, William N.,** 197
***journal of Pharmacy* Technology,** author guidelines JF-ifc, MA-ifc, JA-ifc, SO-ifc; bound volumes, 20, 81, 183; reprints, columns, opinions, and standards MA-ibc, SO-ibc, ND-ibc, major articles JF-ibc, MJ-ibc, JA-ibc; reprints available, 168
***jPT* an Invaluable Resource** (L) 189

## K-L

**Kanamycin sulfate,** interference with amino acid analysis (A) 70
**Klaus, Jennifer R.** (author) Correction: Administration Guidelines for Parenteral Drug Therapy (L) 228
**Ketorolac tromethamine,** approved (WN) 181, (WN) 253
**Krier, Brian P.** (coauthor) see **Yamreudeewong, Weeranuj,** 111
**Labeling requirements,** FDA policy (A) 16
**Laboratory tests,** acid phosphatase (A) 22; alanine aminotransferase (A) 22; albumin (A) 22; aldolase (A) 22; alkaline phosphatase (A) 23; ammonia (A) 23; amylase (A) 23; aspartate aminotransferase (A) 23; bilirubin (A) 24; bone marrow examination (A) 248; calcium (A) 24; carbon dioxide (A) 24; chloride (A) 25; cholesterol (A) 25; cholesterol-HDL (A) 25; complete blood count (A) 243; creatine kinase (A) 25; creatine kinase myocardial band (A) 25; creatinine (A) 25; eosinophil count (A) 248; erythrocyte sedimentation rate (A) 246; gamma-glutamyl transpeptidase (A) 26; glucose (A) 26; glucose-6-phosphate dehydrogenase deficiency screen (A) 247; hemoglobin electrophoresis (A) 247; iron, serum (A) 26, total iron-binding capacity (A) 26; lactic dehydrogenase (A) 26; leukocyte alkaline phosphatase stain (A) 248; lipase (A) 27; lupus erythematosus preparation (A) 248;osmotic fragility (A) 246; phosphorus, inorganic (A) 27; potassium (A) 27; protein, total serum (A) 27; reticulocyte count (A) 247; sickle cell anemia preparation (A) 247; sodium (A) 28; triglycerides (A) 28; urea nitrogen, blood (A) 28; uric acid (A) 28
**Lactacyd,** interference with amino acid analysis (A) 70
**Lactic dehydrogenase,** laboratory test (A) 27
**Legal Setback for California Technicians** (A) 114
**Letters,** Comment: Demand Increases for Accredited Pharmacy Technicians, Bodurka, Ronald P., 228; Comment: IV Guidelines, Bakst, Alan, 4, Messerschmidt, Kim, 140; Comment: Job Satisfaction Survey, Autio, L., 228; Comment: Technician Education, Foust, Alice T., 52, Johnston, Nita, 52; Correction: Administration Guidelines for Parenteral Drug Therapy, Klaus, Jennifer R., 228; *jPT* an Invaluable Resource, MacDonald, Myrna, 189; New Technician Training Program, Gores, Tommy M., 140; Opportunities in the U.S. for Canadian Technicians, Tsuyuki, Susan, 140; USP Position vis-a-vis Generic Drug Quality, Valentino, Joseph G., 189
**Levocarnitine,** oral solution available (WN) 45
**Levodopa,** interference with amino acid analysis (A) 70
**Lincomycin,** interference with amino acid analysis (A) 70
**Lipase,** laboratory test (A) 27
**Literature, From the,** APhA Survey on Technician Policies, *American Pharmacy* (1990), 133; Chair Report for the Professional Affairs Committee, Burelle, Timothy N., *American Journal of Pharmaceutical Education* (1989), 133; Challenges Facing Pharmacy Practice, Nahata, Milap C., *American Pharmacy* (1990), 83; DEA Develops FAX Prescription Policy, *RX Ipsa Loquitur* (1990), 83, Update (1990), 83; Demand Increases for Accredited Pharmacy Technicians, McCormick, E.M., *Pharmacy Times* (1990), 177; Home Infusion Market, *Health Industry Today* (1990), 221; JCPP/NABP Meeting, *ASHP News* (1990), 221; Pharmacy Technicians—What are We Waiting For?, Hershenson, B.R., *American Journal of Pharmaceutical Education* (1989), 178; Pharmacy Technicians—a Neglected Resource?, Hargreaves, A.P., *Australian Journal of Hospital Pharmacy* (1989), 177; Planning for Pharmacy Education in the 21st Century: AACP's Leadership Role, Miller, W.A., *American Journal of Pharmaceutical Education* (1989), 177; Technician-Coordinated Stock Control, *American Journal of Hospital Pharmacy* (1990), 220; What Retail RPhs Think About Pharmacy Technicians, *Wellcome Trends in Pharmacy* (1990), 177
**Lor, Edward** (author) Techniques for Assessment of Nutritional Status (A) 103
**Lyme disease,** blood test introduced (WN) 181
**Lyphomed,** restructuring (WN) 134

## M-N

**MacDonald, Myrna** (author) *jPT* an Invaluable Resource (L) 189
**Madhavan, Suresh** (author) Appropriateness of Switches from Prescription to Over-the-Counter Drug Status: Influence of Demographic and Practice Characteristics on Pharmacist Decision Making (A) 239
**Mafenide,** interference with amino acid analysis (A) 70
**Magnesium,** effect on cardiac function (A) 10
**Makoid, Michael C.** (coauthor) see **Athani, Anuradha V.,** 200
**Malatestinic, William N.** (author) Advances in Hospital Pharmacy Computing (A) 197
**Malnutrition,** metabolic processess associated with (A) 103
**Mangalan, S.** (author) Analysis and Quality Control of Polyherbal Drugs: A Focus on the Herbal Cream Herbinol (A) 166
**Manufacturers,** drug, listing, 151
**Marken, Patricia A.** (author) Flumazenil: A Unique Medication to Reverse the Effects of Benzodiazepines (A) 99
**Marsh, Charles C.** (author) book review, 53
**Massoummi, Fred** (author) Pharmaceutical Manufacturers Listing: 1990 Update (A) 151
**Mastocytosis,** new drug introduced (WN) 86
**Meeting Special Needs of Older Patients** (PF) 175
**Mefloquine,** approved (WN) 181
**Megestrol acetate,** use in patient with cancer anorexia/cachexia (PF) 219
**Messerschmidt, Kim** (author) Comment: IV Guidelines (L) 140
**Metanephrine,** interference with amino acid analysis (A) 71
**Metapranolol,** approved (WN) 181
**Methakote,** interference with amino acid analysis (A) 71
**Methamphetamine hydrochloride,** interference with amino acid analysis (A) 71
**Methenamine mandelate,** interference with amino acid analysis (A) 71
**Methotrexate,** interference with amino acid analysis (A) 71; use for unlabeled conditions (A) 18

**Methyldopa,** interference with amino acid analysis (A) 71
**Millares, Mirta** (coauthor) see **Lor, Edward,** 103
**Misoprostol More Effective than Sucralfate** (PF) 251
**Mitomycin,** use for unlabeled conditions (A) 18
**Mody, Vandana D.** (coauthor) see **Mangalan, S.,** 166
**Moricizine hydrochloride,** introduced (WN) 253
**Mormetanephrine,** interference with amino acid analysis (A) 72
**Morphine sulfate oral solution,** available in single-dose packages (WN) 223
**Nahata, Milap C.** (coauthor) see **Ulrey, Josephine R.,** 63
**Nalbupine hydrochloride,** available in preservative-free form (WN) 223
**Nasogastric tube,** tablet administration (A) 60
**National Association of Boards of Pharmacy,** resolutions calling for regulatory action in pharmacy practice (PF) 175
**Neomycin,** interference with amino acid analysis (A) 72
**Neuroleptic drugs,** ineffective in elderly dementia patients (PF) 219
**New Hampshire,** technician society celebrates first-year anniversary (AN) 174
**New Hampshire Society of Pharmacy Technicians** (AN) 174
**New Officers for 1990-91 Announced** (AN) 174
**Nicardipine Hydrochloride: The First Dyhydropyridine Intravenous Calcium-Channel Antagonist** (A) 93
**Nicardipine hydrochloride,** new calcium antagonist (A) 93; use in myocardial ischemia (A) 96; use in perioperative hypertension (A) 96
**Nonsteroidal antiinflammatory drugs,** 5-lipoxygenase inhibitors emerging as new treatment (PF) 132
**Norepinephrine bitartrate,** interference with amino acid analysis (A) 72
**North Carolina,** Central North Carolina APT chapter, new officers elected (AN) 39
**Nuclear magnetic resonance spectroscopy,** predicting drug effectiveness (WN) 44
**Nutraceuticals,** new regulations necessary (PF) 219
**Nutrition,** guide to vitamins, minerals, and supplements (NP) 142
**Nutritional status,** assessment of (A) 103

## O-P

**Oki, Julie** (author) book review, 92
**Omeprazole,** approved (WN) 181
**Ontario College of Pharmacists,** Guidelines for the Practice of Pharmacy (A) 29
**Ophthalmic suspensions,** FML-S introduced (WN) 85
**Orlando, Patricia L.** (author) book review, 190
**Pandya, Kalpesh K.** (coauthor) see **Mangalan, S.,** 166
**Patel, Ramanbhai B.** (coauthor) see **Mangalan, S.,** 166
**Penicillamine,** interference with amino acid analysis (A) 72
**Penicillin G sodium,** interference with amino acid analysis (A) 72
**Pentamidine,** use in *Pneumocystis carinii* prophylaxis (A) 57
**Pharmaceutical Manufacturers Listing: 1990 Update** (A) 151
**Pharmacists,** accountability for technician performance (A) 171; as technicians (HQ) 199; attitude toward prescription to over-the-counter switches (A) 239; Canadian guidelines (A) 29; community, attitude toward technicians (A) 212; delegating and training of technicians (HQ) 176
**Pharmacodynamics,** models (A) 205; principles (A) 203; relationship to pharmacokinetics (A) 209
**Pharmacokinetics,** models (A) 201; relationship to pharmacodynamics (A) 209
**Pharmacotherapy and the Elderly** (U) 254
**Pharmacy Focus,** ASHP Advisory on Handling Hazardous Drugs, 176; Bacteria Developing Resistance to Latest Antibiotics, 251; Butorphanol Works Better as Nasal Spray, 82; Can MOPP Be Replaced in the Treatment of Hodgkin's Disease?, 40; Circadian Rhythms, 251; Clinical Trials Approved for New AIDS Vaccine, 132; Drug Responses Differ by Ethnic Group, 82; Gastric Cancer Advances Reported, 40; Grants Available for Technical Personnel Conferences, 219; HIV Infection Prevented by AIDS Vaccine, 132; Increase in Rosacea May Occur During Cold Winter Months, 41; 5-Lipoxygenase Inhibitors Show Promise as Broad-Spectrum Antiinflammatory Drugs, 132; MAID Active in Untreated Sarcomas, 41; Meeting Special Needs of Older Patients, 175; Megestrol Acetate in Patients with Cancer Anorexia/Cachexia, 219; Misoprostol More Effective than Sucralfate, 251; Neuroleptics Help Few Elderly Dementia Patients, 219; New Rules Needed for Nutraceuticals, 219; Oral Etoposide Appears to Increase Efficacy, 41; Pharmacy Publications in Trouble? 252; Ten Resolutions Recommended to NABP, 175; Timing of Glaucoma Medication Can Make a Big Difference, 132
**Pharmacy Intervention and the Anesthesia Drug Exchange Drawer** (A) 192
**Pharmacy management,** training lab opened (WN) 85
**Pharmacy Publications in Trouble?** (PF) 252
**Pharmacy technicians,** see also **Education, technician;** see also **Roles, technician;** certification (E) 225; effect on manpower shortage (HQ) 140; government support (HQ) 238; job satisfaction (HQ) 35; law needed (HQ) 110; reduce errors (HQ) 9; shortage of (HQ) 87
**Phenobarbital,** interference with amino acid analysis (A) 72
**Phenylephrine hydrochloride,** interference with amino acid analysis (A) 73
**Phenylpropanolamine,** interference with amino acid analysis (A) 73
**Phenytoin Therapy in a Patient with Recessive Dystrophic Epidermolysis Bullosa** (A) 236
**Phosphorus,** inorganic, laboratory test (A) 27
**Picciano, Vincent** (author) *Pneumocystis carinii* Pneumonia Prophylaxis (A) 57
**Pinacidil,** approved (WN) 181
***Pneumocystis carinii* Pneumonia Prophylaxis** (A) 57
**Polyherbal drugs,** quality assurance (A) 166
**Polymyxin B,** interference with amino acid analysis (A) 73
**Postherpetic neuralgia,** capsaicin three-ounce size introduced (WN) 45
**Potassium,** effect on cardiac function (A) 10; laboratory test (A) 27
**Powers, James E.** (author) Comparison of Methods Used to Prepare Tablets for Nasogastric Tube Administration (A) 60
**Prescribing for Unlabeled Conditions: Patient Benefit or Therapeutic Roulette?** (A) 15
**Prescribing practice,** unlabeled conditions (A) 15
**Primary systemic carnitine deficiency,** levocarnitine solution available (WN) 45
**Primidone,** interference with amino acid analysis (A) 73
**Propafenone,** approved (WN) 181
**Propofol,** approved (WN) 181
**Protein,** total serum, laboratory test (A) 27
**Publications, New,** *1989-1990 Pocketbook of Infectious Disease Therapy* (Bartlett J.), 190; *Cardiology Drug Facts* (E.A. Amsterdam), 92; *Communication Skills in Pharmacy Practice: A Practical Guide for Students and Practitioners* (W.N. Tindall, R.S. Beardsley, C.L. Kimberlin), 53; *Complete Guide to Vitamins, Minerals, & Supplements* (H.W. Griffith), 142; *Drug Regimen Review: A Process Guide for Pharmacists* (W.G. Erwin), 141; *Drugs and the Athlete* (G.I. Wadler, B. Hainline), 53; *Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Edition* (H.C. Ansel, N.G. Popovich), 141; *Regulating Change: The Regulation of Foods, Drugs, Medical Devices and Cosmetics in the 1990s* (Jonathan C. Peck, Kenneth H. Rabin), 228; *The Reverse Effect* (W.A. Heiby), 4; *Training Manual for Intravenous Admixture Personnel, 4th Edition* (M.L. Hunt, Jr.), 4; *USAN and the USP Dictionary of Drug Names* (U.S. Pharmacopeial Convention), 190; *USP XXII-NF XVII. The United States Pharmacopeia—The National Formulary,* 53

## Q-R

**Quality assurance,** generic drugs (L) 189; polyherbal drugs (A) 166; technician involvement in (A) 36
**Quazepam,** use in insomnia treatment (A) 233
**Quotes, Historical, Delegating and Training by Pharmacists,** Francke, D.E., *American Journal of Hospital Pharmacy* (1965), 176; **Dispensing by Technicians,** Heard J.S., *Hospital Pharmacy* (1969), 38; **Government Supports Technicians,** Task Force on Prescription Drugs (1968), 238; **Law for Technicians Needed,** Beahm, M.R., *American Journal of Hospital Pharmacy* (1970), 110; **Medieval Pharmacy,** LaWall C.H., *Four Thousand Years of Pharmacy* (1927), 83; **Pharmacists as Technicians,** Brodie, D.C., Pharmacy-Medicine-Nursing Conference on Health Education Proceedings (1967), 199; **Shortage of Technicians,** Zellmer, W.A., *American Journal of Hospital Pharmacy* (1985), 87; **Small Hospital Technician Duties,** Frazier W., *Bulletin of the American Society of Hospital Pharmacists* (1949), 82; **Survey of Technicians' Duties,** Turnbull, R.T., Bowles, G.C., *American Journal of Hospital Pharmacy* (1965), 110; **Technician Education,** Deno, R.A., Pharmacy-Medicine-Nursing Conference on Health Education Proceedings (1967), 211; **Technician Job Satisfaction,** Coburn, M.J., Gagnon J.P., Eckel F.M., *American Journal of Hospital Pharmacy* (1980), 35; **Technician's Future Role,** Ladinsky J., *American Journal of Pharmaceutical Education* (1970), 14; **Technicians Effect on Manpower Shortage,** Hager G.P.,

*American Journal of Pharmaceutical Education* (1966), 140; **Technicians Reduce Errors,** Roberts C.J., Miller W.A., *Drug Intelligence and Clinical Pharmacy* (1972), 9
**Racemethionine,** interference with amino acid analysis (A) 73
**Ramsey, Michael K.** (author) Interpreting Clinical Hematology Test Results (A) 243; (coauthor) see **Roberts, George H.,** 21
**Reno, Craig B.** (coauthor) see **Underhill, Agatha L.,** 36
**Repetititive motion disorders,** need to change child-resistant packaging (WN) 253
**Resistance,** bacterial, to new antibiotics (PF) 251; beta-lactamase, to cephalosporins (PF) 252
**Review of Drug Use in Gilbert's Syndrome** (A) 111
**Roberts, George H.** (author) Interpretive Clinical Chemistry Laboratory Tests (A) 21; (coauthor) see **Ramsey, Michael K.,** 243
**Robinson, Dennis H.** (author) book review, 141
**Roles, technician,** attitude of pharmacists (A) 212; Canadian guidelines (A) 29; dispensing (HQ) 38; future (HQ) 14; (HQ) 110; in small hospitals (HQ) 82
**Rosacea,** outbreaks in winter (PF) 41
**Rucker, T. Donald** (coauthor) see **Serradell, Joaquima,** 15

## S-T

**Seizures,** epileptic, types of, 147
**Selegiline,** approved (WN) 181
**Seltzer, Joseph L.** (coauthor) see **Goldberg, Michael E.,** 93
**Serradell, Joaquima** (author) Prescribing for Unlabeled Conditions: Patient Benefit or Therapeutic Roulette? (A) 15
**Shingles,** capsaicin three-ounce size introduced (WN) 45
**Sodium,** laboratory test (A) 28
**Spironolactone,** inhibition of aldosterone synthesis (A) 10
**Sucralfate,** effectiveness in ulcer prevention (PF) 251
**Sulfur-containing amino acids,** interference with amino acid analysis (A) 73
**Supplements,** dietary, new regulations needed (PF) 219;
**Swanson, Keith A.** (author) book review, 141
**Technician Involvement in a Quality-Assurance Program** (A) 36
**Technicians and the Goal of Excellence** (A) 169
**Techniques for Assessment of Nutritional Status** (A) 103
**Temazepam,** use in insomnia treatment (A) 233
**Ten Resolutions Recommended to NABP** (PF) 175
**Test Your Knowledge,** answers, 46, 87, 180, 222, 262; questions, 43, 55, 145, 191, 230
**The New Fluoroquinolones: Correlating In Vitro Findings and Clinical Experience** (A) 5
**Therapeutic Trends,** Enzyme Discovery Buttresses Oxidation Theory of Disease, 39; Transgenics, 39
**Timolol,** absorption affected by time of day (PF) 132
**Toradol Approved for Marketing** (WN) 253
**Transgenics,** technological advances (TT) 39
**Triazolam,** use in insomnia management (A) 233
**Triglycerides,** laboratory test (A) 28
**Trimethoprim/sulfamethoxazole,** use in *Pneumocystis carinii* prophylaxis (A) 57
**Tsuyuki, Susan** (author) Opportunities in the U.S. for Canadian Technicians (L) 140
**Turlapaty, Prasad** (coauthor) see **Goldberg, Michael E.,** 93

## U-V

**Ulcers, gastric,** effectiveness of misoprostol and sucralfate (PF) 251
**Ulrey, Josephine R.** (author) Drug Interferences with Amino Acid Analysis (A) 63
**Underhill, Agatha L.** (author) Technician Involvement in a Quality-Assurance Program (A) 36
**Updating Your Skills,** Pharmacotherapy and the Elderly, 254
**Urea nitrogen,** blood, laboratory test (A) 28
**Uric acid,** laboratory test (A) 28
**USP Position vis-a-vis Generic Drug Quality** (L) 189
**Valentino, Joseph G.** (author) USP Position vis-a-vis Generic Drug Quality (L) 189
**Vasodilation,** nicardipine hydrochloride (A) 96
**Vazquez, A.** (author) Phenytoin Therapy in a Patient with Recessive Dystrophic Epidermolysis Bullosa (A) 236
**Verapamil hydrochloride,** Lederle to market (WN) 181; lower-dose Calan SR introduced (WN) 85
**Vincristine sulfate,** unlabeled conditions (A) 18
**Viray, Rico** (coauthor) see **Goldberg, Michael E.,** 93

## W-Z

**Wagner, Jon C.** (author) book review, 53
**Warfarin sodium,** crystalline, new dosage strength introduced (WN) 134
**Weart, C. Wayne** (coauthor) see **Gums, John G.,** 10
**What's New,** Alzheimer's Disease Enzyme Discovered, 85; Baxa Introduces Micro/Macro Compounder, 44; Carnitor Oral Solution Introduced, 45; Child-Resistant Closures and Repetitive Motion Disorders, 253; Codaphen and Roxicodone Intensol New from Roxane, 182; CytoGuard Reduces Drug Aerosolization, 45; Depakote Sprinkle Available, 44; Ethmozine Introduced, 253; Fujisawa to Begin Immunosuppressant Clinical Trials, 85; Insulin Dosage Computer Available, 223; IV Safety Standard with InterLink System, 181; Larger Size Zostrix for Shingles Pain Relief, 45; Lederle to Market Verelan, 181; LifeCare Micro Pump in Epidural Infusion, 134; Lyphomed Restructuring, 134; Medi-Message on Call with Drug Information, 223; Needle Disposal System, 182; New Allergan Ophthalmic Suspension, 85; New Coumadin Dosage Tablet, 134; New Drug Approved for Mastocytosis, 86; New Drugs Approved in 1989, 181; New Lyme Disease Test Introduced, 181; Novo Nordisk Handles Insulin Marketing, 46; Nubain Availability, 223; Ocuvite Introduced, 134; Pharmacy Management Training Lab Opened, 85; Roxanol Rescudose for Pain, 223; Rx Alert—New Medication Reminder, 134; Rx Register Released, 135; Searle Introduces New Lower-Dose Calan SR, 85; Technology Predicts Drug Effectiveness, 44; Timpilo Dispensing Vial Introduced, 86; Toradol Approved for Marketing, 253; Upjohn Dermatology Signs Agreement with Owen/Galderma, 223; Upjohn to Market New Antibiotic, 45
**Whitney, Harvey A.K. Jr.** (author) Commitment: Holding Pharmacy Accountable for Technician Certification (E) 137; Job Satisfaction: *jPT* Survey Results (E) 1; Listening to Technicians (E) 49; Listening to Technicians—Revisited (E) 225; The U.S. Inspector General Views Technicians as Vital (E) 89
**Withdrawal,** antiepileptic drugs (A) 149
**Yamreudeewong, Weeranuj** (author) Review of Drug Use in Gilbert's Syndrome (A) 111
**Zanol, Marie** (coauthor) see **Birdwell, Stephen W.,** 212

## ADVERTISERS

***1989 Administration Guidelines for Parenteral Drug Therapy,*** reprints available, 47, 74
**Harvey Whitney Books,** books, journals, and reprints, 56; Medical Abbreviations, 84, 165; Pediatric Drug Formulations, 62, 150; Pharmacy International Christian Archives, 84; Principles of Pharmacoeconomics, 186; The Practice of Pharmacy, 179